Skip to main content
NCBI home page
International Journal of Biological Sciences logoLink to International Journal of Biological Sciences
. 2006 Nov 1;3(1):40–46. doi: 10.7150/ijbs.3.40

Intrarenal Oxidative Stress and Augmented Angiotensinogen are Precedent to Renal Injury in Zucker Diabetic Fatty Rats

Yuki Suzaki 1, Yuri Ozawa 1, Hiroyuki Kobori 1
PMCID: PMC1657083  PMID: 17200690

Abstract

The Zucker diabetic fatty (ZDF) rat is a model of type II diabetes and metabolic syndrome based on impaired glucose tolerance caused by the inherited insulin-resistance gene. The ZDF rat exhibits progressive nephropathy; however, the detailed mechanisms have remained unclear. This study was performed to examine the possible involvement of enhanced intrarenal angiotensinogen in the development of renal injury in ZDF rats. Genetic pairs of male ZDF rats and control lean rats (N=6 each) were maintained from 12 to 17 weeks of age. At 17 weeks of age, fasting blood glucose and urinary 8-isoprostane levels were significantly higher in ZDF rats compared with the controls. Systolic blood pressure progressively increased in ZDF rats from 120+/-1 to 137+/-1 mmHg during this period. In contrast, systolic blood pressure did not increase in the controls. Kidney angiotensinogen protein levels were significantly increased in ZDF rats compared with the controls (1.83+/-0.34 vs. 1.00+/-0.17, relative ratio). Expression of angiotensin II type 1a receptor mRNA was similar between these groups. The measured indices of renal damage in the present study (glomerular sclerosis, interstitial expansion, glomerular macrophage infiltration, and renal arterial proliferation) were not significantly increased at this stage in ZDF rats. However, we previously showed that the increased reactive oxygen species-related angiotensinogen enhancement plays an important role in the development of renal injury in a genetic salt-sensitive hypertension. Thus, the present data suggest that elevated reactive oxygen species and reactive oxygen species-associated augmentation of intrarenal angiotensinogen may initiate the development of renal injury in ZDF rats.

Keywords: renin-angiotensin system, diabetes mellitus, angiotensinogen, oxidative stress, renal injury

1. Introduction

Diabetic nephropathy is the most common cause of end-stage renal failure in patients starting dialysis in developed countries 1. Clinical trials have demonstrated that high glucose levels are the principal cause of renal damage in both type I 2 and type II diabetes 3. The mechanisms underlying the development of diabetic nephropathy are extremely complex; however, activation of the intrarenal renin-angiotensin (Ang) system (RAS) has been suggested 4-10.

Angiotensinogen is the only known substrate for the enzyme, renin, which cleaves angiotensinogen to release a biologically inactive decapeptide, AngI 11. Angiotensin-converting enzyme (ACE) cleaves a dipeptide from AngI to produce a biologically active peptide, AngII 11. AngII stimulates aldosterone secretion, cell proliferation and migration 12, thrombosis 13, and superoxide production 14-16. All of these factors are involved in development and progression of nephropathy. Our previous reports suggest that AngII stimulates angiotensinogen synthesis and that enhancement of angiotensinogen may be a key component in the maintenance of elevated circulating and intrarenal AngII levels 17-21.

High glucose generates reactive oxygen species (ROS) as a result of glucose auto-oxidation, metabolism, and formation of advanced glycosylation end products 22. AngII also stimulates ROS generation 23. ROS is one of the important mediators of vascular complications in diabetes 4, 22. In addition, we previously showed that angiotensinogen expression is augmented by ROS in salt-sensitive hypertensive rats 24.

The Zucker diabetic fatty (ZDF) rat is considered to be an excellent animal model of type II diabetes that presents a physiological and metabolic profile similar to that seen in humans 25, 26. The ZDF rat is characterized by hyperglycemia, hyperinsulinemia, hyperlipidemia, moderate hypertension, moderate obesity, and progressive renal injury 27, 28. Schafer et al. 29 showed that ZDF rats established diabetes at 17 weeks of age. Coimbra et al. 30 showed that ZDF rats developed focal and segmental sclerosis at 18 weeks of age, although severe hyperlipidemia, hyperglycemia, and obesity predated it. Hoshi et al. 25 reported that ZDF rats showed glomeruloscrerosis as early as 20 weeks of age. Chander et al. showed that ZDF rats developed focal and segmental sclerosis at 22 weeks of age 31. Thus, there are clear data demonstrating that ZDF rats show renal injury starting at 18-20 weeks of age. Although ZDF rats steadily show renal injury around 20 weeks of age, early initiation factors involved in the development of renal injury has not been elucidated in ZDF rats. Mizuno et al. 26 demonstrated that a pharmacological blockade of the RAS with AngII type 1 (AT1) receptor blocker (ARB) reduced proteinuria and delayed the progression of renal disease independently from blood pressure control in ZDF rats. This result has suggested that the activated intrarenal RAS plays an important role in the development of renal injury in ZDF rats. Moreover, in salt sensitive hypertensive rats, we previously reported that the ROS-related activation of intrarenal angiotensinogen plays important roles in the development of renal injury 24. These data prompted us to examine the possible involvement of enhanced ROS-associated augmentation of intrarenal angiotensinogen in the development of nephropathy at the early stage of diabetes in ZDF rats. Therefore, we have focused on intrarenal parameters of ZDF rats before the elicitation of renal injury.

2. Materials and Methods

Animals

The experimental protocol was approved by the Animal Care and Use Committee of Tulane University. Male ZDF rats (ZDF-fa/fa, 12 weeks of age, N=6) and age-matched control male lean rats (ZDF-+/?, 12 weeks of age, N=6) were purchased from Charles River Laboratories. These rats were maintained from 12 to 17 weeks of age. Rats were housed in metabolic cages and maintained in a temperature-controlled room regulated on a twelve-hour light/dark cycle with free access to water. Rats were fed with a commercially available rat chow containing normal salt and 16.7 kcal% fat (Formulab Diet 5008, LabDiet). Fasting blood glucose levels were measured using a glucose analyzer (TheraSense). Systolic blood pressures were measured by tail cuff plethysmography once a week as previously described 17-21, 32.

Urinary Measurements

Twenty-four hour urine samples were collected once a week in centrifuge tubes containing 10 µg/ml of indomethacin and 0.005% butylated hydroxytoluene. Urine samples were centrifuged and the supernatant was separated and stored at –80°C until assayed for total protein and 8-isoprostane. Urinary concentration of total protein was measured by colorimetric assays using a commercially available kit (Bio-Rad). 8-isoprostane is the major urinary metabolite of F2-isoprostanes and is formed non-enzymatically from the action of superoxide radicals on arachidonic acid 33. The urinary 8-isoprostane excretions were measured by ELISA using a commercially available kit (Cayman).

Sample Collections

Blood and kidney samples were harvested at 17 weeks of age. After decapitation, trunk blood was collected into chilled tubes containing 5 mmol/l EDTA, 20 µmol/l enalaprilat, 10 µmol/l pepstatin A, and 1.25 mmol/l 1,10-phenanthroline. Plasma was separated and stored at –20°C until assayed for plasma AngII by radioimmunoassay as previously described 17-21, 32. Immediately after removal, one kidney was homogenized in cold methanol and renal AngII was measured by radioimmunoassay as previously described 17-21, 32. The contralateral kidneys were separated into three pieces and snap-frozen in liquid nitrogen for protein extraction, immersed in RNAlater (Ambion) for total RNA extraction and immersed in zinc-saturated formalin (Anatech) for tissue fixation.

Western Blot Analysis

Protein extraction of renal cortex and Western blot analysis for angiotensinogen were performed as previously described 17-21, 32. Sheep polyclonal antibody against purified rat angiotensinogen was produced and characterized at University of Queensland, Australia 34. Anti beta-actin antibody was purchased from Sigma. Data of Western blot analysis for angiotensinogen protein levels were normalized by beta-actin protein levels.

Quantitative Real-time RT-PCR

Total RNA extraction of renal cortex and quantitative real-time RT-PCR for AT1a receptor were performed as previously described 32. The information of sequences are as follows: AT1a receptor; forward primer, 5'-CTT GTT CCC TTT CCT TAT CA-3', reverse primer, 5'-CGT TTC TTG GTT TGT TCT TT -3', probe, 5'- CAC CAG CTA TAC CCT TAT TTG GAA AGC -3'; GAPDH, forward primer, 5'- CAG AAC ATC ATC CCT GCA TC -3', reverse primer, 5'- CTG CTT CAC CAC CTT CTT GA -3', probe, 5'- CCT GGA GAA ACC TGC CAA GTA TGA TGA -3'. Data of quantitative RT-PCR for AT1a mRNA levels were normalized by GAPDH mRNA levels.

Histological Analysis

Histological samples were embedded in paraffin by an out-sourcing company (Mass Histology). The extent of glomerular sclerosis was evaluated with periodic acid Schiff-stained sections. The extent of interstitial expansion was evaluated with Picro-Sirius red-stained sections. Quantification was performed semi-automatically in a blind manner by using the Image-Pro plus software (Media Cybernetics) as previously described 32.

Immunohistochemistry

Paraffin-embedded sections from the rat kidneys were also used for immunohistochemical analysis with the ABC method (Vector Laboratories). The numbers of monocytes/macrophages in glomeruli were examined by immunohistochemistry using a commercially available antibody against CD68 (ED-1, Serotec) as previously described 32. The magnitude of arterial proliferation of afferent arteriolar walls was evaluated by immunohistochemistry using a commercially available antibody against alpha-smooth muscle isoform of actin (Dako) with elastin stain (Sigma) as previously described 32.

Statistical Analysis

Statistical analysis was performed using paired or unpaired t-test. All data are presented as mean+/-SEM. p<0.05 was considered significant.

3. Results

General Animal Data

The rats' profiles of body weight, fasting blood glucose, urine volume and urine protein excretion at 17 weeks of age are shown in Table 1. The ZDF rats developed diabetes mellitus, as manifested by increases in water intake (ZDF rats: 66+/-17 ml/day vs. control lean rats: 29+/-6 ml/day at 17 weeks of age), urine volume, and blood glucose. The fasting glucose levels were significantly increased in ZDF rats compared to control lean rats. Urine volume and protein excretion also increased in ZDF rats compared to control lean rats.

Table 1.

Characteristics of ZDF rats and control lean rats at 17 weeks of age

Lean ZDF
Body Weight, g 288 ± 7 378 ± 18*
Fasting Blood Glucose, mg/dl 47 ± 5 148 ± 36**
Urine Volume, ml/day 9.8 ± 1.0 44.3 ± 16.6*
Urine Protein, mg/day 6.8 ± 0.6 22.1 ± 2.7**
Open in a new tab

**p<0.01, *p<0.05

Systolic Blood Pressure

Systolic blood pressure was similar between ZDF and control lean rats at 12 weeks of age. ZDF rats showed a moderate increase in systolic blood pressure, which reached a significant level by 15 weeks of age (137+/-1 mmHg) compared with 12 weeks of age (120+/-1 mmHg). The control lean rats did not have increased blood pressures.

Urinary 8-Isoprostane

As shown in Figure 1, urinary 8-isoprostane excretion rates were not different between ZDF and control lean rats at 12 weeks of age. At 15 weeks of age, the urinary 8-isoprostane excretions showed a tendency to increase in ZDF rats and were significantly increased at 17 weeks of age.

Figure 1.

Figure 1

Open in a new tab

The urinary 8-isoprostane excretions of ZDF and control lean rats. The urinary 8-isoprostane was significantly augmented in ZDF rats at 17 weeks of age. **p<0.01 vs. control lean rats at the same age.

Kidney Angiotensinogen Protein

As shown in Figure 2, angiotensinogen protein expression was increased in ZDF rats at 17 weeks of age. No differences in the amount of beta-actin were observed among samples.

Figure 2.

Figure 2

Open in a new tab

Kidney angiotensinogen levels in ZDF and control lean rats at 17 weeks of age. (A) A representative Western blot analysis of angiotensinogen and beta-actin. (B) The densitometric analysis shows that ZDF rats had significantly increased kidney angiotensinogen levels compared to control lean rats. *p<0.05 vs. control lean rats at the same age.

Plasma AngII, Kidney AngII and AT1a Receptor mRNA

As shown in Figure 3, ZDF rats showed slightly increased plasma AngII concentrations. Similar to plasma concentrations, intrarenal AngII contents were also slightly increased in ZDF rats. However, plasma AngII concentrations and kidney AngII contents were not significantly increased in ZDF rats. As shown in Figure 4, AT1a receptor mRNA was not different between ZDF and control lean rats.

Figure 3.

Figure 3

Open in a new tab

Plasma (A) and kidney (B) AngII levels in ZDF and control lean rats at 17 weeks of age. Plasma AngII concentrations and kidney AngII contents were not significantly different between ZDF and control lean rats.

Figure 4.

Figure 4

Open in a new tab

Kidney AT1a receptor mRNA in ZDF and control lean rats at 17 weeks of age. Kidney AT1a receptor mRNA in ZDF were not significantly different compared with control lean rats.

Renal Damage

Glomerular sclerotic index were not different between ZDF and control lean rats (Figure 5A-5C). Interstitial expansive index showed similar levels between ZDF and control lean rats (Figure 5D). Glomerular macrophage infiltration was not significantly increased in ZDF rats (Figure 5E). Afferent arteriolar wall thickness was not altered in ZDF compared to control lean rats (Figure 5F).

Figure 5.

Figure 5

Open in a new tab

Evaluation of renal damage in ZDF and control lean rats at 17 weeks of age. Renal damages were evaluated based on these four parameters: (A-C) glomerular sclerosis index using periodic acid-Schiff stained sections of ZDF (A) and control lean (B) rats, (D) interstitial expansion index using by Picro-Sirius red-stained sections, (E) glomerular macrophage

4. Discussion

In this study, emphasis was placed on evaluating early mediators of renal damage in ZDF rats at 17 weeks of age. Schafer et al. 29 showed that ZDF rats established diabetes at 17 weeks of age. Coimbra et al. 30 showed that ZDF rats developed focal and segmental sclerosis at 18 weeks of age, although severe hyperlipidemia, hyperglycemia, and obesity predated it. Hoshi et al. 25 reported that ZDF rats showed glomeruloscrerosis as early as 20 weeks of age. Chander et al. showed that ZDF rats developed focal and segmental sclerosis at 22 weeks of age 31. Thus, there are clear data demonstrating that ZDF rats show renal injury starting at 18-20 weeks of age, and in the present study, ZDF rats at 17 weeks of age without nephropathy were examined whether augmented intrarenal angiotensinogen is involved in the development of renal injury. We observed that these ZDF rats show the angiotensinogen augmentation before the development of renal injury at 17 weeks of age in this study.

In the present study, we have investigated the possible involvement of the enhanced angiotensinogen in renal injury in ZDF rats. At 17 weeks of age, although ZDF rats were confirmed having high glucose concentration and urine protein, renal damage were not documented by glomerular sclerosis, interstitial expansion, glomerular macrophage infiltration or renal arterial proliferation. Importantly, the oxidative stress and intrarenal angiotensinogen were augmented at this time-point. Therefore, the augmentation of oxidative stress and intrarenal angiotensinogen are precedent to renal damage in ZDF rats.

Recent studies have provided evidence that AngII stimulates intracellular formation of ROS 35, 36. AngII-induced ROS plays a pivotal role in several pathophysiological conditions such as hypertension, endothelial dysfunction, nitrate tolerance, atherosclerosis, and cellular remodeling 37. Although plasma and kidney AngII levels were not significantly increased in ZDF rats, an oxidative stress marker, 8-isoprostane was significantly elevated in ZDF rats at 17 weeks of age. High glucose induces ROS generation via non-enzymatic glycation of proteins or glucose auto-oxidation 22. Hyperglycemia, the main determinant of the initiation and progression of renal injury, not only generates more reactive oxygen metabolites, but also attenuates anti-oxidative mechanisms through non-enzymatic glycosylation of anti-oxidant enzymes 38. It has been reported that 8-isoprostane is enhanced in the setting of diabetes in type I 39 and type II diabetic patients 40. These studies support the concept that high glucose-induced ROS is involved in the setting of renal injury.

Changes in angiotensinogen levels can control the activity of the RAS, and its up-regulation may lead to elevated AngII levels and increases in blood pressure 41. Our previous report suggested that stimulation of angiotensinogen synthesis by AngII may be a key component in the maintenance of elevated intrarenal AngII levels 17. We also reported that angiotensinogen expression is elevated independently from blood pressure in AngII-dependent hypertension 20, 21. Although plasma and kidney AngII levels were not significantly increased in the present study, kidney angiotensinogen protein was increased in ZDF rats. Systolic blood pressure in ZDF rats was also significantly higher than in control lean rats, but this elevation did not reach a hypertensive range. Interestingly, it is reported that angiotensinogen gene expression is induced by high glucose in proximal tubular cells 42. In addition, Hsieh et al. 43 demonstrated that the stimulatory action of high glucose on angiotensinogen gene expression in immortalized renal proximal tubular cells is mediated at least in part via ROS generation. We also showed that augmentation of angiotensinogen is caused by ROS in hypertensive rats 24. Our present data also demonstrate concomitant increases of ROS and angiotensinogen in ZDF rats compared with control lean rats before renal injury in ZDF rats was evident. Our present study thus suggests that ROS and ROS-mediated angiotensinogen activation may have an important role in early mediation of renal injury in ZDF rats.

We failed to demonstrate the enhanced levels of intrarenal AngII in ZDF rats even though the intrarenal AngII levels were maintained by the augmented levels of intrarenal angiotensinogen in ZDF rats. We did not measure plasma renin activity; however, it is well known that plasma renin activity is suppressed in both diabetic patients and animals 4-10. The maintained levels of intrarenal AngII and the augmented levels of intrarenal angiotensinogen may partially account for the renoprotective effects of ARBs and ACE inhibitors in diabetic nephropathy even though the circulating RAS activity is suppressed in diabetes.

Our present study may imply that ZDF rats treated with antioxidant may demonstrate favorable effects on renal levels of angiotensinogen and AngII as well as urinary protein excretion; however, the emphasis of the present study was to report that intrarenal oxidative stress and augmented angiotensinogen are precedent to renal injury in ZDF rats. Practically, it is very difficult to use specific and effective antioxidants in vivo study. Further in vivo and/or in vitro study may be required to clarify these issues.

In summary, we have demonstrated in this study that the augmented oxidative stress and the enhanced intrarenal angiotensinogen precede the development of renal injury in ZDF rats. We previously reported that the ROS-related activation of intrarenal angiotensinogen plays important roles in the development of renal injury in salt sensitive hypertensive rats 24. These data suggest that the augmented ROS and the ROS-associated activation of intrarenal angiotensinogen are involved in the development of renal injury. These mechanisms may partially account for the renoprotective effects of ARBs and ACE inhibitors in the diabetic nephropathy.

Acknowledgments

This study was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK072408), the National Center for Research Resources (P20RR017659), the National Heart, Lung, and Blood Institute (R01HL026371), the Health Excellence Fund from Louisiana Board of Regents, and Sankyo Co. Ltd. (Tokyo, Japan). Y.S. is a recipient of a fellowship from the Kanae Foundation for Life and Socio-medical Science (Tokyo, Japan). The authors acknowledge critical reviews and valuable comments of L. Gabriel Navar, Ph.D. (Tulane University). The authors also acknowledge excellent technical assistances from My-Linh Rauv, Duy V. Tran, Dale M. Seth, and Mark A. Cabrera (Tulane University).

References

  • 1.Joss N, Paterson KR, Deighan CJ, Simpson K, Boulton-Jones JM. Diabetic nephropathy: how effective is treatment in clinical practice? Qjm. 2002;95:41–9. doi: 10.1093/qjmed/95.1.41. [DOI] [PubMed] [Google Scholar]
  • 2.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977–86. doi: 10.1056/NEJM199309303291401. [DOI] [PubMed] [Google Scholar]
  • 3.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–53. [PubMed] [Google Scholar]
  • 4.Nagai Y, Yao L, Kobori H, Miyata K, Ozawa Y, Miyatake A, Yukimura T, Shokoji T, Kimura S, Kiyomoto H, Kohno M, Abe Y, Nishiyama A. Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol. 2005;16:703–11. doi: 10.1681/ASN.2004080649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Carey RM, Siragy HM. The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab. 2003;14:274–81. doi: 10.1016/s1043-2760(03)00111-5. [DOI] [PubMed] [Google Scholar]
  • 6.Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9. doi: 10.1056/NEJMoa011161. [DOI] [PubMed] [Google Scholar]
  • 7.Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456–62. doi: 10.1056/NEJM199311113292004. [DOI] [PubMed] [Google Scholar]
  • 8.Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952–61. doi: 10.1056/NEJMoa042274. [DOI] [PubMed] [Google Scholar]
  • 9.Luno J, Praga M, de Vinuesa SG. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS) Curr Pharm Des. 2005;11:1291–300. doi: 10.2174/1381612053507413. [DOI] [PubMed] [Google Scholar]
  • 10.Hollenberg NK. Renal implications of angiotensin receptor blockers. Am J Hypertens. 2001;14:237S–41S. doi: 10.1016/s0895-7061(01)02133-1. [DOI] [PubMed] [Google Scholar]
  • 11.Skeggs LT Jr, Kahn JR, Lentz K, Shumway NP. The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med. 1957;106:439–53. doi: 10.1084/jem.106.3.439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Dubey RK, Jackson EK, Luscher TF. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin1 receptors. J Clin Invest. 1995;96:141–9. doi: 10.1172/JCI118014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest. 1995;95:995–1001. doi: 10.1172/JCI117809. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Hannken T, Schroeder R, Stahl RA, Wolf G. Angiotensin II-mediated expression of p27Kip1 and induction of cellular hypertrophy in renal tubular cells depend on the generation of oxygen radicals. Kidney Int. 1998;54:1923–33. doi: 10.1046/j.1523-1755.1998.00212.x. [DOI] [PubMed] [Google Scholar]
  • 15.Kawada N, Imai E, Karber A, Welch WJ, Wilcox CS. A mouse model of angiotensin II slow pressor response: role of oxidative stress. J Am Soc Nephrol. 2002;13:2860–8. doi: 10.1097/01.asn.0000035087.11758.ed. [DOI] [PubMed] [Google Scholar]
  • 16.Welch WJ, Mendonca M, Aslam S, Wilcox CS. Roles of oxidative stress and AT1 receptors in renal hemodynamics and oxygenation in the postclipped 2K,1C kidney. Hypertension. 2003;41:692–6. doi: 10.1161/01.HYP.0000052945.84627.8F. [DOI] [PubMed] [Google Scholar]
  • 17.Kobori H, Harrison-Bernard LM, Navar LG. Expression of angiotensinogen mRNA and protein in angiotensin II-dependent hypertension. J Am Soc Nephrol. 2001;12:431–9. doi: 10.1681/asn.v123431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Kobori H, Harrison-Bernard LM, Navar LG. Enhancement of Angiotensinogen Expression in Angiotensin II-Dependent Hypertension. Hypertension. 2001;37:1329–1335. doi: 10.1161/01.hyp.37.5.1329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Kobori H, Harrison-Bernard LM, Navar LG. Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production. Kidney Int. 2002;61:579–85. doi: 10.1046/j.1523-1755.2002.00155.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Kobori H, Nishiyama A, Harrison-Bernard LM, Navar LG. Urinary angiotensinogen as an indicator of intrarenal Angiotensin status in hypertension. Hypertension. 2003;41:42–9. doi: 10.1161/01.hyp.0000050102.90932.cf. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Kobori H, Prieto-Carrasquero MC, Ozawa Y, Navar LG. AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin II-dependent hypertension. Hypertension. 2004;43:1126–32. doi: 10.1161/01.HYP.0000122875.91100.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Ha H, Lee HB. Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose. Kidney Int Suppl. 2000;77:S19–25. doi: 10.1046/j.1523-1755.2000.07704.x. [DOI] [PubMed] [Google Scholar]
  • 23.Liu J, Yang F, Yang XP, Jankowski M, Pagano PJ. NAD(P)H oxidase mediates angiotensin II-induced vascular macrophage infiltration and medial hypertrophy. Arterioscler Thromb Vasc Biol. 2003;23:776–82. doi: 10.1161/01.ATV.0000066684.37829.16. [DOI] [PubMed] [Google Scholar]
  • 24.Kobori H, Nishiyama A. Effects of tempol on renal angiotensinogen production in Dahl salt-sensitive rats. Biochem Biophys Res Commun. 2004;315:746–50. doi: 10.1016/j.bbrc.2004.01.120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Hoshi S, Shu Y, Yoshida F, Inagaki T, Sonoda J, Watanabe T, Nomoto K, Nagata M. Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats. Lab Invest. 2002;82:25–35. doi: 10.1038/labinvest.3780392. [DOI] [PubMed] [Google Scholar]
  • 26.Mizuno M, Sada T, Kato M, Koike H. Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes. Hypertens Res. 2002;25:271–8. doi: 10.1291/hypres.25.271. [DOI] [PubMed] [Google Scholar]
  • 27.Vora JP, Zimsen SM, Houghton DC, Anderson S. Evolution of metabolic and renal changes in the ZDF/Drt-fa rat model of type II diabetes. J Am Soc Nephrol. 1996;7:113–7. doi: 10.1681/ASN.V71113. [DOI] [PubMed] [Google Scholar]
  • 28.Etgen GJ, Oldham BA. Profiling of Zucker diabetic fatty rats in their progression to the overt diabetic state. Metabolism. 2000;49:684–8. doi: 10.1016/s0026-0495(00)80049-9. [DOI] [PubMed] [Google Scholar]
  • 29.Schafer S, Linz W, Bube A, Gerl M, Huber J, Kurzel GU, Bleich M, Schmidts HL, Busch AE, Rutten H. Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats. Cardiovasc Res. 2003;60:447–54. doi: 10.1016/s0008-6363(03)00544-3. [DOI] [PubMed] [Google Scholar]
  • 30.Coimbra TM, Janssen U, Grone HJ, Ostendorf T, Kunter U, Schmidt H, Brabant G, Floege J. Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int. 2000;57:167–82. doi: 10.1046/j.1523-1755.2000.00836.x. [DOI] [PubMed] [Google Scholar]
  • 31.Chander PN, Gealekman O, Brodsky SV, Elitok S, Tojo A, Crabtree M, Gross SS, Goligorsky MS. Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen. J Am Soc Nephrol. 2004;15:2391–403. doi: 10.1097/01.ASN.0000135971.88164.2C. [DOI] [PubMed] [Google Scholar]
  • 32.Kobori H, Ozawa Y, Suzaki Y, Nishiyama A. Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats. J Am Soc Nephrol. 2005;16:2073–80. doi: 10.1681/ASN.2004080676. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol. 1997;17:2309–15. doi: 10.1161/01.atv.17.11.2309. [DOI] [PubMed] [Google Scholar]
  • 34.Thomas WG, Sernia C. Immunocytochemical localization of angiotensinogen in the rat brain. Neuroscience. 1988;25:319–41. doi: 10.1016/0306-4522(88)90029-2. [DOI] [PubMed] [Google Scholar]
  • 35.Onozato ML, Tojo A, Goto A, Fujita T, Wilcox CS. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int. 2002;61:186–94. doi: 10.1046/j.1523-1755.2002.00123.x. [DOI] [PubMed] [Google Scholar]
  • 36.Griendling KK, Ushio-Fukai M. Reactive oxygen species as mediators of angiotensin II signaling. Regul Pept. 2000;91:21–7. doi: 10.1016/s0167-0115(00)00136-1. [DOI] [PubMed] [Google Scholar]
  • 37.Wolf G. Free radical production and angiotensin. Curr Hypertens Rep. 2000;2:167–73. doi: 10.1007/s11906-000-0078-z. [DOI] [PubMed] [Google Scholar]
  • 38.Wolff SP, Jiang ZY, Hunt JV. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med. 1991;10:339–52. doi: 10.1016/0891-5849(91)90040-a. [DOI] [PubMed] [Google Scholar]
  • 39.Davi G, Chiarelli F, Santilli F, Pomilio M, Vigneri S, Falco A, Basili S, Ciabattoni G, Patrono C. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation. 2003;107:3199–203. doi: 10.1161/01.CIR.0000074205.17807.D0. [DOI] [PubMed] [Google Scholar]
  • 40.Davi G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Costantini F, Capani F, Patrono C. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation. 1999;99:224–9. doi: 10.1161/01.cir.99.2.224. [DOI] [PubMed] [Google Scholar]
  • 41.Ichihara A, Kobori H, Nishiyama A, Navar LG. Renal renin-angiotensin system. Contrib Nephrol. 2004;143:117–30. doi: 10.1159/000078716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Wang TT, Wu XH, Zhang SL, Chan JS. Effect of glucose on the expression of the angiotensinogen gene in opossum kidney cells. Kidney Int. 1998;53:312–9. doi: 10.1046/j.1523-1755.1998.00775.x. [DOI] [PubMed] [Google Scholar]
  • 43.Hsieh TJ, Fustier P, Wei CC, Zhang SL, Filep JG, Tang SS, Ingelfinger JR, Fantus IG, Hamet P, Chan JS. Reactive oxygen species blockade and action of insulin on expression of angiotensinogen gene in proximal tubular cells. J Endocrinol. 2004;183:535–50. doi: 10.1677/joe.1.05871. [DOI] [PubMed] [Google Scholar]

Articles from International Journal of Biological Sciences are provided here courtesy of Ivyspring International Publisher

RESOURCES